3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 3
2
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Breast
2
Tumor-Agnostic
1
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
81
Nivolumab
55
Ipilimumab
44
Cyclophosphamide
37
aldesleukin
26
Interleukin-2
25
Temozolomide
17
fludarabine
16
fludarabine phosphate
15
trametinib
11
dabrafenib
11
Radiotherapy
11
Biopsy
11
avelumab
10
Paclitaxel
9
spartalizumab
8
cemiplimab
8
Dacarbazine
8
Cisplatin
8
Bevacizumab
8
sargramostim
7
binimetinib
7
Fluorouracil
7
poly ICLC
6
lenvatinib
6
epacadostat
6
atezolizumab
6
Magnetic Resonance Spectroscopy
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
montanide ISA 51
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Colony-Stimulating Factors
×
Dermatologic
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled